Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro

Clinical Cancer Research

Volumn 4, Issue 11, 1998, Pages 2895-2902

  Marshman, Emma ^a   Newell, David R ^a   Calvert, A Hilary ^a   Dickinson, Anne M ^b   Patel, Hitendra R H ^a   Campbell, F Charles ^a   Curtin, Nicola J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD34 ANTIGEN; DIPYRIDAMOLE; FOLIC ACID ANTAGONIST; GLYCINE HYDROXYMETHYLTRANSFERASE; HYPOXANTHINE; LOMETREXOL; N [5 [2 (2 AMINO 1,4,5,6,7,8 HEXAHYDRO 4 OXOPYRIDO[2,3 D]PYRIMIDIN 6 YL)ETHYL] 2 THENOYL]GLUTAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SELECTIVITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PURINE SYNTHESIS; SMALL INTESTINE; TISSUE SPECIFICITY; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL DIVISION; DIPYRIDAMOLE; DRUG SYNERGISM; FOLIC ACID ANTAGONISTS; GROWTH INHIBITORS; HEMATOPOIETIC STEM CELLS; HUMANS; HYPOXANTHINE; INTESTINES; K562 CELLS; MICE; MICE, INBRED BALB C; TETRAHYDROFOLATES; TUMOR CELLS, CULTURED;

EID: 0031724435     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Beardsley, G. P., Moroson, B. A., Taylor, E. C., and Moran, R. G. A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J. Biol. Chem., 264: 328-333, 1989.
2. Shin, C., Grindey, G. B., Houghton, P. J., and Houghton, J. A. In vivo antitumor activity of DDATHF and its diastereomer isomers. Proc. Am. Assoc. Cancer Res., 29: 283, 1988.
3. Ray, M. S., Muggia, F. M., Leichman, C. G., Grunberg, S. M., Nelson, R. L., Dyke, R. W., and Moran, R. G. Phase I study of DDATHF: a folate antimetabolite inhibitory of de novo purine synthesis. J. Natl. Cancer Inst. (Bethesda), 85: 1154-1159, 1993.
4. Laohavunij, S., Wedge, S. R., Lind, M. J., Bailey, N., Humphreys, A., Proctor, M., Chapman, F., Simmons, D., Oakley, A., Robson, L., Gumbrell, L., Taylor, G. A., Thomas, H. D., Boddy, A. V., Newell, D. R., and Calvert, A. H. A Phase 1 clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid. Invest. New Drugs, 14: 325-335, 1996.
5. Mendelsohn, L. G., Shih, C., Schultz, R. M., and Worzalla, J. F. Biochemistry and pharmacology of glycinamide ribonucleotide formyltransferase inhibitors: LY309887 and lometrexol. Invest. New Drugs, 14: 287-294, 1996.
6. Habeck, L. L., Leitner, T. A., Shackelford, K. A., Gossett, L. S., Schultz, R. M., Andis, S. L., Shih, C., Grindey, G. B., and Mendelsohn, L. G. A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res., 54: 1021-1026, 1994.
7. Weber, G. Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer Res., 43: 3466-3492, 1983.
8. Fox, M., Boyle, J. M., and Kinsella, A. R. Nucleoside salvage and resistance to antimetabolite anticancer agents. Br. J. Cancer, 69: 205-211, 1991.
9. Kinsella, A. R., and Harran, M. S. Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts. Cancer Res., 51: 1855-1859, 1991.
10. Pizzorno, G., Moroson, B. A., Cashmore, A. R., and Beardsley, G. P. (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid effects on nucleotide metabolism in CCRF-CEM human T-lymphoblast leukemia cells. Cancer Res., 51: 2291-2295, 1991.
11. Erba, E., Sen, S., Sessa, C., Vikhanskaya, F. L., and D'Incalci, M. Mechanism of cytotoxicity of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of drug activity by folic and folinic acid. Br. J. Cancer. 69: 205-211. 1994.
12. Plagemann, P. G. W., Wohlhueter, R. M., and Woffendin, C. Nucleoside and nucleobase transport in animal cells. Biochim. Biophys. Acta, 947: 405-443, 1988.
13. Hughes, J. M., and Tattersall, M. H. Potentiation of methotrexate lymphotoxicity in vitro by inhibitors of nucleoside transport. Br. J. Cancer, 59: 381-384, 1989.
14. Van Mouweric, T. J., Pangallo, C., Willson, J. K. V., and Fischer, P. H. Augmentation of methotrexate cytotoxicity by human colon cancer cells achieved through inhibition of thymidine salvage by dipyridamole. Biochem. Pharmacol., 36: 809-814, 1987.
15. Curtin, N. J., Harris, A. L., and Aherne, G. W. Mechanism of cell death following thymidylate synthase inhibition: 2′-deoxyuridine-5′-triphosphate accumulation. DNA damage and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res., 51: 2346-2352, 1991.
16. Chan, T. C. K., and Howell, S. B. Role of hypoxanthine and thymidine in determining methotrexate plus dipyridamole cytotoxicity. Eur. J. Cancer, 26: 907-911, 1990.
17. Turner, R. M., Aherne, G. W., and Curtin, N. J. Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage. Br. J. Cancer, 76: 1300-1307, 1997.
18. Chen, T. R. In situ detection of mycoplasma contamination in cell culture by fluorescent Hoechst 33258 stain. Exp. Cell Res., 104: 255-262, 1977.
19. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. (Bethesda), 82: 1107-1112, 1990.
20. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 150: 76-85, 1985.
21. Evans, G. S., Flint, N., Somers, A. S., Eyden, B., and Potten, C. S. The development of a method for the preparation of rat intestinal epithelial cell primary cultures. J. Cell Sci., 101: 219-231, 1992.
22. Kasper, M., Stosiek, P., Typlt, H., and Karsten, U. Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues. Eur. J. Cancer Clin. Oncol., 23: 137-147, 1987.
23. Sutherland, D. R., Stewart, A. K., and Keating, A. CD34 antigen: molecular features and potential clinical applications. Stem Cells. 11 (Suppl. 3): 50-57, 1993.
24. Traycoff, C. M., Abboud, M. R., Laver, J., Brandt, J. E., Hoffman, R., Law, P., Ishizawa, L., and Srour, E. F. Evaluation of the in vitro behavior of phenotypically defined populations of umbilical cord blood hematopoietic progenitor cells. Exp. Hematol., 22: 215-222, 1994.
25. Ademokun, J. A., Chapman, C., Dunn, J., Lander, D., Mair, K., Proctor, S. J., and Dickinson, A. M. Umbilical cord blood collection and separation for hematopoietic progenitor cell banking. Bone Marrow Transplant., 19: 1023-1028, 1997.
26. Slaughter, R. S., and Barnes, E. M., Jr. Hypoxanthine transport by Chinese hamster lung fibroblasts: kinetics and inhibition by nucleosides. Arch. Biochem. Biophys., 197: 349-355, 1979.
27. Domin, B. A., Mahony, W. B., and Zimmerman, T. P. Purine nucleobase transport in human erythrocytes. J. Biol. Chem., 263: 9276-9284, 1988.
28. Domin, B. A., Mahony, W. B., and Zimmerman, T. P. Transport of 5-fluorouracil and uracil into human erythrocytes. Biochem. Pharmacol., 46: 503-510, 1993.
29. Lajtha, L. G., and Vane, J. R. Dependence of bone marrow cells on the liver for purine supply. Nature (Lond.), 182: 191-120, 1958.
30. Tattersall, M. H. N., Slowiaczek P., and De Fazio, A. Regional variation in human extracellular purine levels. J. Lab. Clin. Med., 102: 411-420, 1983.
31. Kwong F. Y. P., Fincham, H. E., Davies, A., Beaumont, N., Henderson, P. J. F., Young, J. D., and Baldwin, S. A. Mammalian nitrobenzylthioinosine-sensitive nucleoside transport proteins. J. Biol. Chem., 267: 21954-21960, 1992.